RxDoctor Payments Data

Iryna Kinzer, PA

Physician Assistant · Redlands, CANPI 1003380593

Payments from drug & device makers

$7,335in general payments, 2019–2025

Across 379 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Sanofi$1K
  • Johnson & Johnson$1K
  • UCB, Inc.$576
  • Novartis$508
  • Amgen$484
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$7,02096%
  • Education$3154%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,335 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$206,214
Medicare patients
405
Services billed
2,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab27$365,726
Skyrizi PenRisankizumab-Rzaa13$266,465
OtezlaApremilast35$192,393
HumiraAdalimumab13$170,920
Humira(Cf) PenAdalimumab22$147,952
Humira PenAdalimumab19$123,667
RinvoqUpadacitinib18$122,656
Dupixent PenDupilumab15$54,881
Dupixent SyringeDupilumab13$48,067
Calcipotriene64$13,475
Clobetasol Propionate261$12,433
Ketoconazole446$10,671
Triamcinolone Acetonide446$6,853
Tacrolimus29$6,649
Ivermectin16$5,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,084$365,72627 claims
AbbVieHumira, Rinvoq$1,520$293,57631 claims
AmgenOtezla$484$192,39335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Redlands

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →